Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 74
Sex differences in semaglutide muscle loss
A July 2026 study finds female ob/ob mice are protected from semaglutide-induced muscle loss while males are not. What the finding means and what it does not.
ONWARDS 8: icodec plus semaglutide in T2D
ONWARDS 8 found that adding weekly semaglutide to weekly insulin icodec cut HbA1c by 1.23 points and body weight by 3.85 kg, with low hypoglycaemia rates.
Plant protein and GLP-1 GI side effects
A 20-person pilot found a plant-based protein shake eased GI symptoms and boosted protein intake in GLP-1 users.
SEMA-VR: semaglutide and vessel cell repair
Semaglutide expanded endothelial precursor cells by 66% in a randomized trial, pointing to a vascular-repair mechanism behind its early cardiovascular benefit.
Semaglutide dissolving microneedle patch
A July 2026 paper in AAPS PharmSciTech tests L-arginine as a semaglutide stabiliser in a dissolving microneedle matrix. Preclinical only; no human data yet.
Semax before bed: reading the sleep reports
Community users report vivid dreams after Semax. No trial has tested this, but the mechanisms the literature documents could explain the observation.
Tirzepatide, CAVI, and arterial stiffness
A 2026 retrospective cohort found tirzepatide reduced CAVI from borderline to normal, alongside weight loss and glycaemic improvements, over 12.7 months.
Tirzepatide breast cancer: 2026 correction
A June 2026 Cureus correction updated an author affiliation in a tirzepatide and breast cancer narrative review. The scientific findings are unchanged.
Tirzepatide in type 1 diabetes: new data
A July 2026 cohort found 10% mean weight loss and lower insulin needs when tirzepatide was added to insulin in adults with type 1 diabetes.
Dapagliflozin plus semaglutide: BMI classes
A 328-patient Saudi cohort: proportional BMI response to dapagliflozin is uniform across obesity classes; semaglutide add-on helps most in class I.
GLP-1 drugs and micronutrient risk
How GLP-1 receptor agonists and dual incretin drugs create vitamin and mineral gaps, which nutrients are most at risk, and what monitoring looks like.
GLP-1 neuro research: what 20 years shows
A 2026 bibliometric analysis mapped 1,202 publications on GLP-1 receptor agonists in neurodegenerative disease from 2006 to 2025.